ReviewFrontiers in pharmacology2025
Clinical and basic research advances on Jinlong capsule for the prevention and treatment of liver cancer.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomes-loaded with traditional Chinese medicine constituents: a novel therapeutic avenue for aplastic anemia.Chinese medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary liver cancer, characterized by an insidious onset, rapid progression, high degree of heterogeneity, difficulties in treatment, and a short survival time, poses a significant threat to human health. Jinlong capsule (JLC), an original drug developed in China, is a Chinese patent medicine used to treat liver cancer. Research has demonstrated the antitumor effects of JLC, attributed to its unique preparation process. When used in combination with modern treatment methods, JLC helps in preventing and treating liver cancer recurrence and metastasis, prolonging patient survival, increasing the tumor objective response rate, alleviating gastrointestinal adverse reactions, enhancing survival quality, regulating immune functions of the body, relieving clinical symptoms, and improving patient safety. This study provides a review of clinical and basic research results on JLC. Methods: We performed literature searches in the Cochrane Library, Embase, PubMed, OVID Scopus, China Biology Medicine, China National Knowledge Infrastructure, VIP, and Wanfang databases for articles published from database inception to December 2023. Results: Basic research has revealed that the effects of JLC include the inhibition of tumor growth Discussion: By attuning to the complex biological characteristics of liver cancer, harnessing the unique and unconventional advantages of traditional Chinese medicine, and focusing on clinical needs, we propose directions for future evidence-based research on using JLC in the prevention and treatment of liver cancer. This will contribute to the development of precision synergistic strategies that combine traditional Chinese medicine and modern medicine treatment methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.